Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase I...
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group
Subjects
More information
Scope and Contents
Contents
To evaluate the time course of clinical response following anifrolumab treatment in patients with SLE.
A post hoc analysis was conducted using pooled data from phase III, randomised, 52-week, placebo-controlled, Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP)-1 and TULIP-2 trials of intravenous anifrolumab (every 4 weeks, 48 w...
Alternative Titles
Full title
Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9843193
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9843193
Other Identifiers
ISSN
2053-8790
E-ISSN
2053-8790
DOI
10.1136/lupus-2022-000761
